相关实验视频

Updated: Jan 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

转录基因引导的药物重定位识别了塞卢美替尼布用于侵袭性上皮癌

Sonja Dorfer¹, Roland Zauner¹, Christina Guttmann-Gruber¹

¹EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg, Austria.

The Journal of investigative dermatology

|December 21, 2025

概括

作为MEK抑制剂的塞卢美替尼布对治疗复发性形表皮溶解牛 (RDEB-SCC) 中的侵袭性状细胞癌具有前景. 这种候选药物在临床前研究中有效降低了瘤生长和入侵.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
药理学药理学是指药理学的学科.

背景情况:

衰退性缩性表皮溶解牛相关状细胞癌 (RDEB-SCC) 在有限的治疗条件下具有攻击性.
对于RDEB-SCC而言,有必要制定新的治疗策略.

研究的目的:

通过计算查确定的一种MEK抑制剂塞卢美替尼布作为RDEB-SCC的潜在治疗方法.
评估塞卢美提尼布在RDEB-SCC的体外和体内疗效.

主要方法:

转录组指导的计算药物查以识别塞卢美替尼布.
在体外测试评估细胞活力,ERK酸化,上皮细胞-介质细胞转换标记物 (E-cadherin,vimentin),运动性,侵入性,PD-L1,MHC-I和细胞因子表达.
在体内异种移植研究评估瘤生长和-ERK水平.
RNA测序用于识别治疗反应生物标志物 (EGR1,FOS,DUSP6).

主要成果:

在实验室中,塞卢梅替尼布降低了RDEB-SCC细胞活力,ERK酸化和瘤细胞入侵.
它诱导了介质细胞到上皮细胞的过渡,并调节了免疫标记物 (PD-L1,MHC-I).
在体内,塞鲁美提尼布抑制了瘤生长,降低了-ERK水平,EGR1,FOS和DUSP6被确定为潜在的生物标志物.

结论:

塞卢梅提尼布显示出对RDEB-SCC的显著临床前疗效.
这些发现支持塞卢梅替尼布作为RDEB-SCC治疗的临床候选者的潜力.

关键词:

计算型药物查是指使用计算机进行药物查.药物重用是为了改变药物的用途.皮肤表面溶解牛皮质.状细胞癌瘤是状细胞癌.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...